Subscribe to NRx Newsletter

NRXP

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions – Adds New U.S. Patent to Portfolio

NRx Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,576,911. This patent, issued to Glytech LLC, is exclusively licensed to NeuroRx, Inc., a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international.

Class Action Suit Against NRx Pharmaceuticals Dismissed

NRx Pharmaceuticals, Inc. is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned “Dal Bosco v. NRx Pharmaceuticals, Inc. et al.” filed a notice in the U.S. District Court for the District of Delaware voluntarily dismissing the action against NRx Pharmaceuticals and its former officers.  The dismissal was made without prejudice.